OMER Earnings

OMER reported its FY2025Q4 earnings on 2026-03-11, showcasing a revenue of against an estimate of 12.40M, resulting in a 0% surprise. The EPS was 0, surpassing the expected -0.55 by 0%. The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following OMER's FY2025Q4 earnings announcement on 2026-03-11, the stock price moved by 0% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, OMER's stock price tends to shift by an average of 10.55% in the 10 days leading up to earnings and 7.01% in the 10 days following, providing insight into potential market.

For , analysts estimate OMER's annual revenue to reach undefined, while the EPS is projected at -0.48. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between OMER's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, OMER's stock price typically moves by 10.55% in the 10 days before its earnings and 7.01% in the 10 days after. For the upcoming earnings, analysts expect an EPS of -0.48 and revenue of undefined.

The earnings call highlights significant revenue growth, improved margins, and reduced losses, indicating strong financial health. Positive feedback on YCANTH, sales force expansion, and strategic positioning further support a positive sentiment. Despite some uncertainties in the EU filing timeline and specific KPIs, the overall outlook, including optimistic guidance and strategic initiatives, suggests a positive stock price movement. The absence of major negative factors and the potential market expansion for YCANTH contribute to the positive rating.